Cargando…
Discovery of Novel 1,2,3-triazole Derivatives as IDO1 Inhibitors
Indoleamine 2,3-dioxygenase 1 (IDO1) has received much attention as an immunomodulatory enzyme in the field of cancer immunotherapy. While several IDO1 inhibitors have entered clinical trials, there are currently no IDO1 inhibitor drugs on the market. To explore potential IDO1 inhibitors, we designe...
Autores principales: | Hou, Xixi, Gong, Xiaoqing, Mao, Longfei, Zhao, Jie, Yang, Jianxue |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9695734/ https://www.ncbi.nlm.nih.gov/pubmed/36355488 http://dx.doi.org/10.3390/ph15111316 |
Ejemplares similares
-
Discovery of Icotinib-1,2,3-Triazole Derivatives as IDO1 Inhibitors
por: Mao, Long-fei, et al.
Publicado: (2020) -
Discovery of a Series of Theophylline Derivatives Containing 1,2,3-Triazole for Treatment of Non-Small Cell Lung Cancer
por: Ye, Jiahui, et al.
Publicado: (2021) -
Discovery of a Series of 1,2,3-Triazole-Containing Erlotinib Derivatives With Potent Anti-Tumor Activities Against Non-Small Cell Lung Cancer
por: Sun, Ge, et al.
Publicado: (2022) -
Synthesis and Antitumor Activity of Erlotinib Derivatives Linked With 1,2,3-Triazole
por: Deng, Peng, et al.
Publicado: (2022) -
Design and synthesis of cabotegravir derivatives bearing 1,2,3-triazole and evaluation of anti-liver cancer activity
por: Xie, Huaxia, et al.
Publicado: (2023)